CN1500514A - Oral colon-positioned triperygium wilfordii composition and its use - Google Patents
Oral colon-positioned triperygium wilfordii composition and its use Download PDFInfo
- Publication number
- CN1500514A CN1500514A CNA021487626A CN02148762A CN1500514A CN 1500514 A CN1500514 A CN 1500514A CN A021487626 A CNA021487626 A CN A021487626A CN 02148762 A CN02148762 A CN 02148762A CN 1500514 A CN1500514 A CN 1500514A
- Authority
- CN
- China
- Prior art keywords
- colon
- pharmaceutical composition
- radix tripterygii
- tripterygii wilfordii
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention is orally taken colon releasing threewingnut composition. The colon releasing mode may be pH sensing type, colon bacteria or enzyme sensing type or time depending type. The composition will not be dissolved in the stomach and the upper section of small intestine, and its effective components will be released in the lower section of ileum or ileocecal part for taking action locally in colon, resulting in raised curative effect and lowered side effect in treating ulcer colitis and colon carcinoma.
Description
The present invention relates to pharmaceutical preparation and uses thereof, specifically relate to Radix Tripterygii Wilfordii colon targeting preparation and preparation method, the purposes of described preparation is treatment ulcerative colitis and colon cancer.
Radix Tripterygii Wilfordii has immunosuppressive action, therefore immunosuppressive disease such as rheumatoid arthritis is had very sure curative effect.Ulcerative colitis also is an immunosuppressive disease, also reports much with Radix Tripterygii Wilfordii treatment ulcerative colitis in recent years, all obtains effect preferably.Radix Tripterygii Wilfordii also has anticarcinogenesis.
The toxicity of Radix Tripterygii Wilfordii is bigger.Have 20% patient to take approximately to occur behind the tripterygium glycosides gastrointestinal upset (as feel sick, mild pain, vomiting, diarrhoea, loss of appetite etc.) but can tolerate.Have 6% patient that leukopenia takes place approximately, thrombocytopenia takes place in 1% patient, and degree is lighter.Tripterygium glycosides can also cause menoxenia and motility of sperm to reduce, and quantity reduces.
Radix Tripterygii Wilfordii has two: one to the effect of body, to gastrointestinal local irritant effect; The 2nd, absorb the back to central nervous system's infringement of (comprising Thalamus, midbrain, oblongata, cerebellum and spinal cord), and can cause that the hemorrhage of liver, heart is with downright bad.According to the observation to a Radix Tripterygii Wilfordii poisoning case surplus 20, the performance of poisoning is stomachache, the struggle of vomitting, suffer from diarrhoea, yelp, but does not generate heat.Death all in 24 hours, is no more than 4 days at most.(Chinese medicine voluminous dictionary, 2469, the new medical college in Jiangsu, Shanghai, Shanghai science tech publishing house)
Ulcerative colitis and colon cancer are the pathological changes at colon position, therefore adopt medicine topical therapeutic meaning very great.
The objective of the invention is to reduce the toxicity of Radix Tripterygii Wilfordii, development treatment ulcerative colitis and the effective Radix Tripterygii Wilfordii colon location preparation of colon cancer, because preparation discharges at terminal ileum or colonic, make the local Radix Tripterygii Wilfordii concentration height of pathological changes, more help the treatment of ulcerative colitis and colon cancer and avoided the stimulation of Radix Tripterygii Wilfordii the harmonization of the stomach small intestinal, owing to seldom absorb at the colonic medicine, the untoward reaction that is absorbed the Radix Tripterygii Wilfordii that causes by whole body also can obviously reduce simultaneously.
Radix Tripterygii Wilfordii of the present invention refers to extract or the composite of Radix Tripterygii Wilfordii, wherein contains tripterygium glycosides, Tripterygium glycosides, triptolide (C
6H
13 (14)O
6), NSC-163063, Triptolide, wilfordine (Wilfordine), Radix Tripterygii Wilfordii throw away one or more of alkali (Wilforine), wilforgine (Wilforgine), wilfortrine (Wilfortrine), wilfozine (Wilforzine), celastrol (Celastrol), dulcitol and other effective ingredient.
Colon location preparation of the present invention adopts three types, i.e. pH responsive type, intracolic antibacterial or enzyme responsive type, time-dependent.
Conlon targeting mode of the present invention can be the pH responsive type.The conlon targeting material of pH responsive type (or claiming excipient) can be the acroleic acid resin class, as the Youteqi of German Romo Co.,Ltd
(Eudragit
), home-made acroleic acid resin II number and acroleic acid resin III number, also can be cellulose acetate phenolphthalein ester (CAP).The dosage form of pH responsive type colon location preparation of the present invention can be the form of tablet and capsule.Specifically be in flakes with the Radix Tripterygii Wilfordii compacting, the above-mentioned conlon targeting material of reuse coating; Perhaps Radix Tripterygii Wilfordii is made piller, the above-mentioned conlon targeting material of reuse coating reinstalls conventional capsule or common enteric coated capsule; The conventional capsule of perhaps Radix Tripterygii Wilfordii being packed into, the above-mentioned conlon targeting material of reuse coating, the colon site-specific drug of perhaps Radix Tripterygii Wilfordii directly being packed into, the preparation method of colon site-specific drug are common Capsuleses with above-mentioned conlon targeting material coating.The content of Radix Tripterygii Wilfordii in the colon locating administrated compositions of Radix Tripterygii Wilfordii pH responsive type of the present invention is 0.01%-90%, and the weightening finish of pH responsive type colon enteric coating is 1%-6%.
Colon location preparation for pH dependent form, the thickness of the coating of coating material and pH sensitivity no less important, both are relations that this disappears and other rises, that is to say within the specific limits, if the dissolving pH of coating material is low, then the thickness of coating will be greatly, if the dissolving pH of coating material is high, then the thickness of coating will be smaller.The dissolving pH limit of Youteqi L100 is 6.0, the dissolving pH limit of Youteqi S100 is 7.0, if two kinds of material mixing are made coating material, will obtain the dissolved coating of beginning between pH6.0-7.0, if the ratio height of Youteqi L100 in the composite material, then the coating dissolving is early very fast, so coating should be thicker, greatly between the 150-300 micron; If the ratio height of Youteqi S100 in the composite material, then the coating dissolving is later slower, so coating should be thinner, greatly between the 70-150 micron.
Conlon targeting form of the present invention also can be intracolic antibacterial or enzyme responsive type.Colonic has a large amount of antibacterials, and antibacterial can account for the 20%-30% of solid amount, and wherein some antibacterial can produce β-Pu Taotanggansuanmei, beta-glucosidase, cellulase, nitroreductase, azo reductase etc.Seldom, and abundant in colon, these enzymes have the specificity degradation capability to some material to these enzymes simultaneously, utilize this point can prepare the colon administration system in the harmonization of the stomach small intestinal.This class material comprises pectin, amylose, azobenzene polymer, disulphide polymer, chitosan, guar gum, cross-linked glucose, chrondroitin, ethyl cellulose and their mixture.
Pectin is a kind of water soluble polysaccharide, is not degraded by the enteral enzyme of harmonization of the stomach, but can be degraded by intracolic some bacteriogenic enzyme, utilizes this characteristic can be applied to colon location preparation.But pectin has water solublity, is directly used in colon locating administrated weak effect, and after its calcification become calcium pectinate, water solublity reduced, and degraded character is constant, is ideal conlon targeting material therefore.Abroad the someone has prepared calcium pectinate compression coated tablets and matrix tablet, has all shown good conlon targeting.Have and studies show that calcium content and its conlon targeting effect in the calcium pectinate are closely related, the calcic rate influences the water solublity of calcium pectinate, and the existence of calcium ion influences the power of enzyme to the calcium pectinate Degradation.The Zhang Jun longevity proposes calcium content conlon targeting effective in the 5%-12% scope in patent CN1326733.
When the present invention used calcium pectinate as the conlon targeting material, dosage form can be tablet and capsule.The preparation method of tablet is that Radix Tripterygii Wilfordii and calcium pectinate are pressed into the calcium pectinate matrix tablet, and the content of Radix Tripterygii Wilfordii is 0.01%-90% in the Radix Tripterygii Wilfordii calcium pectinate matrix tablet of the present invention, and the content of calcium pectinate is 20%-80%; Perhaps in flakes with the Radix Tripterygii Wilfordii compacting, reuse calcium pectinate pressed coated, the content of Radix Tripterygii Wilfordii is 0.01%-90% in the calcium pectinate coated tablet of Radix Tripterygii Wilfordii of the present invention, the weightening finish of coating is 2%-20%.The preparation method of capsule can be that Radix Tripterygii Wilfordii and calcium pectinate are made granule or piller, pack into conventional capsule or common enteric coated capsule; The calcium pectinate colon enteric coated capsule of perhaps Radix Tripterygii Wilfordii and adjuvant directly being packed into.The preparation method of calcium pectinate colon enteric coated capsule is the mould rod to be immersed pectin solution earlier immersing the calcium chloride solution calcification.
The conlon targeting mode that the present invention adopts also can be a time dependence conlon targeting mode, utilizes the gastrointestinal transhipment time to reach the purpose of conlon targeting exactly.The transhipment time of small intestinal is relatively stable, and the influence of unable to take food thing or medicine-releasing system character was generally 4 ± 1 hours.This kind drug-supplying system is generally used the hydrophobic material coating, and coating is designed to slowly corrode, and discharges medicine behind preset time.This class hydrophobic material comprises ethyl cellulose, carnaubic acid, Cera Flava, single oleic acid polyoxyethylene mannitol.
Time dependence conlon targeting mode dosage form of the present invention can be tablet and capsule.Specifically be in flakes with the Radix Tripterygii Wilfordii compacting, the above-mentioned conlon targeting mixtures of material of reuse or a kind of coating wherein, the content of the Radix Tripterygii Wilfordii among the present invention is 0.01%-90%, the weightening finish of coating is 1%-20%; The dissolved time set of coating of the present invention is 5-6 hour, specifically is that simulated gastric fluid did not dissolve in 2 hours, does not dissolve dissolving in 1 hour in the simulated intestinal fluid of pH7.8 in the simulated intestinal fluid of pH6.8 in 3 hours.Perhaps Radix Tripterygii Wilfordii is made piller, the above-mentioned conlon targeting material of reuse coating, reinstall conventional capsule or common enteric coated capsule, if pack conventional capsule into, the dissolved time set of coating of the present invention is 5-6 hour, the common enteric coated capsule if pack into, then the dissolution time of piller coating is set at 3-4 hour.The content of Radix Tripterygii Wilfordii among the present invention is 0.01%-90%, and the weightening finish of piller coating is 1%-10%; The conventional capsule of perhaps Radix Tripterygii Wilfordii being packed into, the above-mentioned conlon targeting material of reuse coating, the content of the Radix Tripterygii Wilfordii among the present invention is 0.01%-90%, the weightening finish of coating is 1%-10%.The dissolved time set of coating of the present invention is 5-6 hour.The pulsincap (Pulsincap) of also Radix Tripterygii Wilfordii can being packed into reaches the conlon targeting release purpose.Pulsincap is the location releasing mechanism basically identical of system therewith.This capsular capsule medicated cap enteric solubility material coating, utricule is then used insoluble material coating.After this medicine-releasing system enters small intestinal, capsule medicated cap dissolving, the water-setting plug at bladder aperture place is exposed to and absorbs moisture in the environment of intestinal juice and expand, and its expansible speed depends on the crosslinking degree of this gel.After after a while, separate with utricule, medicine then from utricule rapid release come out.Necessary long enough of the expansion time of water-setting plug, so that medicine-releasing system is transported to colon, the loading amount of the Radix Tripterygii Wilfordii of each pulsincap of the present invention is 0.03mg-500mg, the expansion time of water-setting plug is 3-5 hour.
The dissolution in vitro of the colon location preparation of Radix Tripterygii Wilfordii of the present invention adopts " the method under 2000 editions two appendix tablet items of Chinese pharmacopoeia, but the method is not defined in the test period in the phosphate buffer of pH6.8, design is 3 hours with this time according to the present invention, and all the other are identical to draw following method: not disintegrate in 2 hours does not discharge in 37 ℃ of simulated gastric fluids; Not disintegrate in 3 hours does not discharge in 37 ℃ of pH6.8 simulated intestinal fluids; Stripping in 1 hour is more than 70% in 37 ℃ of pH7.8 simulated intestinal fluids.
The location research method adopts the method for Li Hanyun in the barium sulfate spike of Chinese patent CN1334083 proposition in the body of the present invention.Though do not have active component in the preparation of this method because conlon targeting is mainly to realize by coating, localized whether accurate be fully the prescription of coating and technology decision and with content in whether active component is arranged or barium sulfate has nothing to do.Concrete grammar is barium sulfate to be made colon location preparation take, and carries out x-ray in certain time interval and checks, the film making record.
Following examples are in order to illustrate further the present invention, rather than scope of the present invention is provided constraints.
Example 1pH responsive type Radix Tripterygii Wilfordii colon location preparation-Tripterygium glycosides colon enteric coated capsule
Tripterygium glycosides 10.0g
Starch 50.0g
Dextrin 50.0g
Magnesium stearate 1.5g
The conventional capsule of more than packing into.
The prescription of colon enteric coating coating solution:
Youteqi L 12.5g
Youteqi S 37.5g
Diethyl phthalate 5.0g
Pulvis Talci 8.0g
Alcohol 95 0.0g
With above-mentioned colon enteric coating coating solution above-mentioned Tripterygium glycosides conventional capsule coating is promptly got Tripterygium glycosides colon enteric coated capsule.This Tripterygium glycosides colon enteric coated capsule is carried out the dissolution in vitro result of the test: in 37 ℃ of simulated gastric fluids 2 hours, stripping was lower than 1%; The 3h stripping is lower than 1% in 37 ℃ of pH6.8 simulated intestinal fluids; The 1h stripping is more than 90% in 37 ℃ of pH7.8 simulated intestinal fluids.
With the barium sulfate conventional capsule of packing into, with above-mentioned colon enteric coating coating solution coating, make barium sulfate spike capsule, carried out tracking test in five person-times of bodies, x-ray checks, the film making record, the result shows, take this capsule after, wherein a people obeys three barium sulfate spike capsules all in the whole disintegrates of ileocecus, one people obeys all disintegrates in ascending colon of three barium sulfate spike capsules, and it is the terminal ileum position that its excess-three people obeys three disintegrate position, sees Table 1.
The capsular disintegrate of table 1 barium sulfate spike position
| The disintegrate position | Number |
| Terminal ileum | ????3 |
| Ileocecus | ????1 |
| Ascending colon | ????1 |
| Transverse colon | ????0 |
Example 2pH responsive type Radix Tripterygii Wilfordii colon location preparation-Tripterygium glycosides colon enteric coated capsule
The capsule heart prescription of Tripterygium glycosides colon enteric coated capsule
Tripterygium glycosides 10.0g
Starch 50.0g
Dextrin 50.0g
Magnesium stearate 1.5g
The above-mentioned colon enteric hollow capsule (production of Chaozhou, Guangdong capsule for medicine factory) of more than packing into.
This Tripterygium glycosides colon enteric coated capsule is carried out the dissolution in vitro result of the test: in 37 ℃ of simulated gastric fluids 2 hours, stripping was lower than 1%; The 3h stripping is lower than 1% in 37 ℃ of pH6.8 simulated intestinal fluids; The 1h stripping is more than 85% in 37 ℃ of pH7.8 simulated intestinal fluids.
With barium sulfate this colon enteric hollow capsule of packing into, make barium sulfate spike capsule, carried out tracking test in five person-times of bodies, x-ray checks, the film making record, the result shows, after taking this capsule, wherein three people obey three barium sulfate spike capsules all in the whole disintegrates of ileocecus, and a people obeys all disintegrates in ascending colon of three barium sulfate spike capsules, it is the terminal ileum position that one people obeys three disintegrate position, sees Table 2.
The capsular disintegrate of table 2 barium sulfate spike position
| The disintegrate position | Number |
| Terminal ileum | ????1 |
| Ileocecus | ????3 |
| Ascending colon | ????1 |
| Transverse colon | ????0 |
Example 3pH responsive type Radix Tripterygii Wilfordii colon location preparation-Tripterygium glycosides colon enteric coatel tablets
The prescription of Tripterygium glycosides label
Tripterygium glycosides 10.0g
Starch 50.0g
Icing Sugar 30.0g
Dextrin 40.0g
10% starch slurry is an amount of
Magnesium stearate 1.5g
The prescription of colon enteric coating coating solution
Youteqi L 12.5g
Youteqi S 37.5g
Diethyl phthalate 5.0g
Pulvis Talci 10.0g
80% alcohol 95 0.0g
Prescription by above-mentioned Tripterygium glycosides label is made sheet, and the prescription of the above-mentioned colon enteric coating of reuse coating solution carries out coating and promptly gets Tripterygium glycosides colon enteric coatel tablets.
These Tripterygium glycosides colon enteric coatel tablets are carried out the dissolution in vitro result of the test: in 37 ℃ of simulated gastric fluids 2 hours, stripping was lower than 1%; The 3h stripping is lower than 1% in 37 ℃ of pH6.8 simulated intestinal fluids; The 1h stripping is more than 85% in 37 ℃ of pH7.8 simulated intestinal fluids.
With the barium sulfate compacting in flakes, carry out coating with above-mentioned colon enteric coating coating solution and make barium sulfate spike sheet, carried out tracking test in five person-times of bodies, x-ray checks, the film making record, and the result shows, after taking this sheet, wherein three people to obey the disintegrate position of three barium sulfate spike sheets be the terminal ileum position, two people obey three and are ileocecus, see Table 3.
The capsular disintegrate of table 3 barium sulfate spike position
| The disintegrate position | Number |
| Terminal ileum | ????3 |
| Ileocecus | ????2 |
| Ascending colon | ????0 |
| Transverse colon | ????0 |
Example 4 antibacterials or enzyme responsive type Radix Tripterygii Wilfordii colon location preparation-Tripterygium glycosides colon enteric coated capsule
The preparation of antibacterial or enzyme responsive type Capsules-calcium pectinate Capsules:
15% hypo-methoxy pectin (LMP) aqueous solution 100ml
5%CaCl
2Alcohol-water (7: 3) solution 100ml
5%PVP ethanol liquid 100ml
8% acroleic acid resin II number pure liquid 100ml
Coating liquid paraffin on the clean excellent mould immerses 15%LMP liquid then and proposes after 30 seconds, immerses 5%CaCl again
2Ethanol (70%) liquid, calcification (60 ℃) 1 hour places 35 ℃, dry up under the RH35% condition, immersed 5%PVP ethanol liquid again 2 minutes, propose to put 35 ℃, blow under the RH35% condition near and do, 8% acroleic acid resin II number pure liquid of back immersion 1 minute proposes to dry up promptly.
The capsule heart prescription of Tripterygium glycosides colon enteric coated capsule
Tripterygium glycosides 10.0g
Starch 50.0g
Dextrin 50.0g
Magnesium stearate 1.5g
The above-mentioned colon enteric hollow capsule of more than packing into promptly gets Tripterygium glycosides colon enteric coated capsule.
This Tripterygium glycosides colon enteric coated capsule is carried out the dissolution in vitro result of the test: in 37 ℃ of simulated gastric fluids 2 hours, stripping was lower than 1%; The 3h stripping is lower than 1% in 37 ℃ of pH6.8 simulated intestinal fluids; The 1h stripping is more than 80% in 37 ℃ of pH7.8 simulated intestinal fluids.
With barium sulfate this colon enteric hollow capsule of packing into, make barium sulfate spike capsule, carried out tracking test in five person-times of bodies, x-ray checks, the film making record, the result shows, take this capsule after, wherein four-player is obeyed all disintegrates in ascending colon of three barium sulfate spike capsules, a people obey three barium sulfate spike capsules all in transverse colon whole disintegrates see Table 4.
The capsular disintegrate of table 4 barium sulfate spike position
| The disintegrate position | Number |
| Terminal ileum | ????0 |
| Ileocecus | ????0 |
| Ascending colon | ????4 |
| Transverse colon | ????1 |
Example 5 time-dependent Radix Tripterygii Wilfordii colon enteric coated preparation-Tripterygium glycosides colon enteric coated capsulees
The capsule heart prescription of Tripterygium glycosides colon enteric coated capsule
Tripterygium glycosides 10.0g
Starch 50.0g
Dextrin 50.0g
Magnesium stearate 1.5g
The pulsincap (Pulsincap) of more than packing into promptly gets Tripterygium glycosides colon enteric coated capsule.
This Tripterygium glycosides colon enteric coated capsule is carried out the dissolution in vitro result of the test: in 37 ℃ of simulated gastric fluids 2 hours, stripping was lower than 1%; The 3h stripping is lower than 1% in 37 ℃ of pH6.8 simulated intestinal fluids; The 1h stripping is more than 90% in 37 ℃ of pH7.8 simulated intestinal fluids.
With the barium sulfate pulsincap of packing into, make barium sulfate spike capsule, carried out tracking test in five person-times of bodies, x-ray checks, the film making record, the result shows, after taking this capsule, wherein two people obey three barium sulfate spike capsules all in the whole disintegrates of terminal ileum, and two people obey three barium sulfate spike capsules all in the whole disintegrates of ileocecus, one people obeys all disintegrates in ascending colon of three barium sulfate spike capsules, sees Table 5.
The capsular disintegrate of table 5 barium sulfate spike position
| The disintegrate position | Number |
| Terminal ileum | ????2 |
| Ileocecus | ????2 |
| Ascending colon | ????1 |
| Transverse colon | ????0 |
According to the present invention, the term conventional capsule comprises gelatine capsule, starch capsule and HPMC capsule.
Claims (15)
1, a kind of compositions of oral colon positioning feed, but comprising the Radix Tripterygii Wilfordii of treatment effective dose and the pharmaceutically acceptable excipient of extract or composite and conlon targeting release medicine thereof.
2, pharmaceutical composition as claimed in claim 1, wherein Radix Tripterygii Wilfordii and extract thereof or composite are selected from tripterygium glycosides, Tripterygium glycosides, triptolide, NSC-163063, Triptolide, wilfordine, Radix Tripterygii Wilfordii and throw away one or more of alkali, wilforgine, wilfortrine, wilfozine, celastrol, dulcitol and other effective ingredient.
3, pharmaceutical composition as claimed in claim 1, wherein pharmaceutically acceptable excipient comprises acroleic acid resin.
4, pharmaceutical composition as claimed in claim 3, wherein a kind of in acroleic acid resin be selected from acroleic acid resin enteric II number, acroleic acid resin enteric III number and their mixture thereof.
5, as the pharmaceutical composition in the claim 3, wherein acroleic acid resin is selected from Youteqi
L100, Youteqi
S100 and Youteqi
A kind of among the L30D and their mixture.
6, as the pharmaceutical composition in the claim 1, wherein pharmaceutically acceptable excipient comprises cellulose acetate phenolphthalein ester.
7, pharmaceutical composition as claimed in claim 1, wherein excipient is selected from a kind of in pectin salt, amylose, azobenzene polymer, disulphide polymer, chitosan, guar gum, cross-linked glucose, chrondroitin, the ethyl cellulose and their mixture.
8, pharmaceutical composition as claimed in claim 7, wherein pectin salt is selected from one of calcium pectinate, pectin ferrum, pectin zinc.
9, pharmaceutical composition as claimed in claim 8, wherein the calcium content of calcium pectinate is 5%-12%.
10, pharmaceutical composition as claimed in claim 1, wherein cladding material is selected from a kind of in ethyl cellulose, carnaubic acid, Cera Flava, the single oleic acid polyoxyethylene mannitol and their mixture.
11, pharmaceutical composition as claimed in claim 1, wherein cladding material is a pulsincap.
12, as the pharmaceutical composition of one of claim 1-10, be capsule, tablet, pilule.
13, as the pharmaceutical composition of one of claim 1-10, be coated preparation, wherein the thickness of coating is the 70-300 micron.
14, be used for the treatment of purposes in the medicine of ulcerative colitis and colon cancer as the oral colon positioning feed compositions of one of claim 1-11 in preparation.
15, as the purposes of claim 14, described drug main will discharge at colon and/or terminal ileum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021487626A CN1500514A (en) | 2002-11-19 | 2002-11-19 | Oral colon-positioned triperygium wilfordii composition and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021487626A CN1500514A (en) | 2002-11-19 | 2002-11-19 | Oral colon-positioned triperygium wilfordii composition and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1500514A true CN1500514A (en) | 2004-06-02 |
Family
ID=34233317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021487626A Pending CN1500514A (en) | 2002-11-19 | 2002-11-19 | Oral colon-positioned triperygium wilfordii composition and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1500514A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103070956A (en) * | 2013-03-02 | 2013-05-01 | 河南中医学院 | Biological adhesion colon positioning micro-chip for treating ulcerative colitis |
| CN113367247A (en) * | 2021-01-05 | 2021-09-10 | 安徽科技学院 | Feed additive for preventing broiler chicken myogastric and glandular gastritis |
| CN114272266A (en) * | 2021-12-22 | 2022-04-05 | 首都医科大学附属北京友谊医院 | Application of triptolide combined with dendritic cells |
-
2002
- 2002-11-19 CN CNA021487626A patent/CN1500514A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103070956A (en) * | 2013-03-02 | 2013-05-01 | 河南中医学院 | Biological adhesion colon positioning micro-chip for treating ulcerative colitis |
| CN103070956B (en) * | 2013-03-02 | 2014-09-17 | 河南中医学院 | Biological adhesion colon positioning micro-chip for treating ulcerative colitis |
| CN113367247A (en) * | 2021-01-05 | 2021-09-10 | 安徽科技学院 | Feed additive for preventing broiler chicken myogastric and glandular gastritis |
| CN113367247B (en) * | 2021-01-05 | 2023-11-14 | 安徽科技学院 | Feed additive for preventing stomach proventriculitis of broiler chickens |
| CN114272266A (en) * | 2021-12-22 | 2022-04-05 | 首都医科大学附属北京友谊医院 | Application of triptolide combined with dendritic cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1111402C (en) | The multiple dose unit formulation of tramadol | |
| US20100233253A1 (en) | Extended release gastro-retentive oral drug delivery system for valsartan | |
| KR20040018394A (en) | Gastric retention controlled drug delivery system | |
| KR20030013460A (en) | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition | |
| CN1356893A (en) | New formulation | |
| CA2121038C (en) | Oral preparation for release in lower digestive tracts | |
| CN1623533A (en) | Drug formulation with controlled release of active ingredient | |
| CN101249081A (en) | Administer orally controlled release drug administration pharmaceutical tablet | |
| CN1903368A (en) | Targeted, control-release and thin film coating material made of denatured starch for oral medicine to treat colonic diseases, its prepn. and use | |
| CN1500514A (en) | Oral colon-positioned triperygium wilfordii composition and its use | |
| CN102441019A (en) | Chinese medicinal chrysanthemum buccal tablet | |
| CN1843505A (en) | Compound Doxycycline lysozyme enteral capsule | |
| KR20090119986A (en) | Time-specific delayed/pulsatile release dosage forms | |
| CN101791298B (en) | Colon delivery tablet by using pectin / corn protein as coating | |
| WO2019115501A1 (en) | Oral gastroretentive sustained-release pharmaceutical formulation | |
| CN101073573A (en) | Oral beta-lactam antibiotic slow-release composition | |
| Patel et al. | A review: Gastroretentive drug delivery systems and its rational in peptic ulcer treatment | |
| CN101084921A (en) | Active carbon intestinal bioadhesive preparation and preparation method thereof | |
| CN1493300A (en) | Argimycin oral colon orientation administration composition and use | |
| CN1543943A (en) | Oral silybin sustained release agent and preparation thereof | |
| Sungthongjeen et al. | Design of floating HPMC matrix tablets: Effect of formulation variables on floating properties and drug release | |
| CN1267094C (en) | Orally disintegrating tablet of safflor yellow and its preparation process | |
| WO2002102415A1 (en) | Gastric floating system | |
| CN103006611A (en) | Omeprazole enteric bilayer slow-release tablet | |
| CN1181827C (en) | Oral drug delivery system for enhancing the bioavailability of activated glycyrrhetin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Li Mei Document name: Second notice of examination advice |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Li Mei Document name: Deemed as a notice of withdrawal (Trial) |